Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) Enterprise Value (2023 - 2026)

Mangoceuticals' Enterprise Value history spans 3 years, with the latest figure at -$35441.0 for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 96.64% to -$35441.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$35441.0, a 96.64% decrease, with the full-year FY2025 number at -$35441.0, down 96.64% from a year prior.
  • Enterprise Value hit -$35441.0 in Q4 2025 for Mangoceuticals, up from -$499962.0 in the prior quarter.
  • Over the last five years, Enterprise Value for MGRX hit a ceiling of -$36.0 in Q1 2024 and a floor of -$1.2 million in Q3 2023.
  • Historically, Enterprise Value has averaged -$242570.5 across 3 years, with a median of -$26782.0 in 2025.
  • The widest YoY moves for Enterprise Value: up 96.31% in 2025, down 50236.11% in 2025.
  • Tracing MGRX's Enterprise Value over 3 years: stood at -$16942.0 in 2023, then decreased by 6.38% to -$18023.0 in 2024, then tumbled by 96.64% to -$35441.0 in 2025.
  • Business Quant data shows Enterprise Value for MGRX at -$35441.0 in Q4 2025, -$499962.0 in Q3 2025, and -$18123.0 in Q2 2025.